News

Durham, NC-A fluocinolone acetonide sustained drug delivery system (Retisert, Bausch & Lomb) implanted in patients with chronic macular edema associated with retinal venous occlusive disease reduced the edema and improved visual acuity in a significant portion of the eyes of 19 patients enrolled in the first 12 months of a 3-year study.

Charleston, SC-Pediatric cataract surgery with IOL implantation and primary posterior capsulectomy plus vitrectomy is associated with a satisfactory outcome, especially in children operated on after their first birthday, said Rupal H. Trivedi, MD, MSCR.

Wilkes Barre, PA-Bilateral implantation of the apodized diffractive IOL (AcrySof ReSTOR, Alcon Laboratories) appears to result in a high rate of complaints about intermediate vision that can be completely mitigated by implanting the ReSTOR IOL in one eye and the second-generation refractive multifocal IOL (ReZoom, Advanced Medical Optics) contralaterally, according to a study by Frank A. Bucci Jr., MD, a private practitioner in Wilkes-Barre, PA.

Salt Lake City-Implantation of a hydrophilic acrylic IOL (C-flex, Rayner) presoaked in a solution containing a fourth-generation fluoroquinolone resulted in anterior aqueous humor concentrations of antibiotic that were significantly higher and more persistent than what was achieved with a topical drop administration protocol, according to the results of a preclinical study undertaken by Guy Kleinmann, MD, and colleagues at the John A. Moran Eye Center, University of Utah Health Science Center, Salt Lake City.

Previously, ophthalmic viscosurgical devices (OVDs) could be divided into two camps: dispersive OVDs and cohesive OVDs. Both have pros and cons. Cohesive OVDs create and maintain space, they don't trap air bubbles against the endothelium, and they are easy to remove at the end of the surgery. However, they don't coat tissues well.

Baltimore-Cataract surgery in eyes with posterior polar cataracts presents a special challenge, but safety may be optimized with a customized approach that recognizes that not all posterior polar cataracts are alike and employs techniques for minimizing the risk of posterior capsule rupture, said Robert S. Weinberg, MD.

Salt Lake City-Failure to recognize late opacification of the MemoryLens IOL (CIBA Vision) as a cause for vision problems can have potentially negative consequences, including unnecessary surgery and complications secondary to those procedures, said Jonathan G. Haymore, MD.

Cataract surgery using phacoemulsification is perhaps the most important surgical procedure that ophthalmology residents learn during their 3 years of training and is the "bread-and-butter" procedure for practicing ophthalmologists. It goes without saying, therefore, that the entire ophthalmologic community should do its best to ensure outstanding training for the next generation-this usually requires both adequate surgical volume and excellent supervision by the attending surgeon.

The subject of residents' surgical skills during phaco are coming under close scrutiny at various institutions. Two of three institutions concluded that the key to improved outcomes is adequate wet-lab training, expert supervision, and increased phaco conferences. The third is developing a valid instrument to evaluate performance during phaco; the results would provide immediate feedback to the resident by the attending surgeon.

Raleigh, NC-Children in North Carolina now must undergo vision screening before entering kindergarten, due to a law signed in September by Mike Easley, the state's governor.

San Francisco-Athenagen Inc., a privately held biopharmaceutical company, has begun phase I clinical testing of ATG003, its topical eye drop therapy for age-related macular degeneration (AMD).

Conduct an Internet search for references to Eugene de Juan, MD, and it will produce millions of results linking to his world-renowned son and retina specialist, Eugene de Juan Jr., MD. However, the junior Dr. de Juan wants the world to know and remember the great work of his general ophthalmologist father, who practiced with grace and compassion for more than 40 years in Mobile, AL.

Rockville, MD-Vision and ophthalmic researchers in the United States have been narrowing their specifications for requested human eye tissue at the same time that the country's eye banks have been facing federal regulations and state laws that make it more difficult for them to meet these needs. The result is a reduction in tissue available for research. But researchers and eye banks can take steps to address this situation. Without such action, future research into some blinding diseases may be threatened.

San Francisco-Stephen D. McLeod, MD, is the new chairman of the Department of Ophthalmology at the University of California, San Francisco (UCSF).

Alcon Laboratories has received FDA approval to market a new, benzalkonium chloride (BAK)-free formulation of travoprost 0.004% ophthalmic solution (Travatan Z). Prescribers can expect the product to be available by the end of the month.

The results of Ophthalmology Times' 11th annual survey to determine the Best Overall programs as well as Best Clinical, Research, and Residency programs in ophthalmology lists many familiar names among the Top 10. The difference largely comes as they swap positions on the list, each jockeying for prominence in the hearts and minds of ophthalmology leaders nationwide.

Talecris Biotherapeutics granted Bausch & Lomb the exclusive license to recombinant plasmin technology for use in ophthalmology. Bausch & Lomb and Talecris Biotherapeutics co-developed rPlasmin, a recombinant derivative of the human blood component plasmin. The enzyme degrades many blood plasma proteins, including fibrin clots.

Advanced Medical Optics Inc. (AMO) launched its Tecnis CL silicone IOL, which reduces spherical aberrations, improves functional vision, and improves night-driving simulator performance. This IOL replaces the company’s Z9000 and Z9001 Tecnis silicone IOL models.

The FDA approved Alcon Laboratories’ travoprost ophthalmic solution 0.004% (Travatan Z) for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, who are intolerant of, or have insufficient response to other IOP-lowering medication.